ZOM Company Profile and Key Details

Q: Who are the executives of ZOM?

Mr. Evan St. PeterVice President of Technology InnovationMr. Anthony K. BlairChief Operating OfficerMs. Karen DeHaan-Fullerton J.D.Gen. Counsel, Chief Counsel & Corporation Sec.Dr. Stephanie Laine Morley D.V.M., DVMConsultantDr. William Carpenter MacArthurConsultantMs. Kristin DomanskiVice President of HRMr. Larry C. Heaton IIPres, Chief Executive Officer & DirectorMs. Nicole WestfallVice President of MarketingMr. Adrian LockVice President, GM & Head of SalesMs. Ann Marie Cotter CPAChief Financial OfficerMr. Robert W. DiMarzoConsultantMr. Peter L. Donato BSBA, M.B.A.Chief Financial OfficerMr. Greg BlairVice President of Bus. Devel. & Strategic PlanningMs. Karen L. DeHaan-Fullerton J.D.Chief Counsel & Corporation Sec.

AMEX : ZOM

Zomedica

$0.10

-0.0002-0.21%

Open: 9:50 AM

Not Actively Trading

68.15

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

Zomedica Corp. (ZOM) stock declined over -0.21%, trading at $0.10 on AMEX, down from the previous close of $0.10. The stock opened at $0.09, fluctuating between $0.09 and $0.10 in the recent session.

Stock Snapshot

0.0975

Prev. Close

95.35M

Market Cap

0.092

Day Low

-1.6216666666666666

P/E Ratio

-0.06

EPS (TTM)

-0.02

Cash Flow per Share

0.09

Open

979.95M

Number of Shares

0.0973

Day High

98.13%

Free Float in %

0.24

Book Value

790.94K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Mar 27, 2025	0.05	0.06	0.05	0.06	1.36M
Mar 26, 2025	0.06	0.07	0.06	0.06	2.14M
Mar 25, 2025	0.07	0.07	0.06	0.06	1.17M
Mar 24, 2025	0.06	0.07	0.06	0.07	2.18M
Mar 21, 2025	0.08	0.08	0.05	0.06	7.91M
Mar 19, 2025	0.07	0.08	0.07	0.08	7.28M
Mar 17, 2025	0.05	0.07	0.05	0.07	15.2M
Mar 14, 2025	0.04	0.05	0.04	0.05	13.16M
Mar 11, 2025	0.03	0.04	0.03	0.04	7.35M
Mar 07, 2025	0.04	0.04	0.03	0.03	59.31M
Mar 06, 2025	0.04	0.05	0.03	0.04	31.21M
Mar 04, 2025	0.09	0.10	0.09	0.10	790.94K
Mar 03, 2025	0.11	0.11	0.10	0.10	6.04M
Feb 28, 2025	0.11	0.11	0.11	0.11	2.93M
Feb 27, 2025	0.11	0.11	0.09	0.10	7.75M
Feb 26, 2025	0.11	0.11	0.10	0.11	5.27M
Feb 25, 2025	0.12	0.12	0.11	0.11	5.76M
Feb 24, 2025	0.12	0.12	0.12	0.12	5.5M
Feb 21, 2025	0.12	0.12	0.12	0.12	3.91M
Feb 20, 2025	0.12	0.12	0.12	0.12	2.38M

Contact Details

Ann Arbor, MI 48108

United States

https://www.zomedica.com 734 369 2555

About Company

Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA platform, which offers point-of-care diagnostic products for disease states in dogs and cats; and PulseVet, provides for treatment of various musculoskeletal issues, such as broken bones, tendonitis, and torn ligaments in horses and small animals. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and markets a novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.

Stock Peers

APUS

Apimeds Pharmaceuticals US, Inc$1.88 YCBD-PA

0.21141+18.51%

cbdMD, Inc.$1.35 YCBD

0.018+2.28%

cbdMD, Inc.$0.81 CPHI

-0.0185-2.77%

China Pharma Holdings, Inc.$0.65 MNK

-0.0599-14.97%

Mallinckrodt plc$0.34

Company Overview

The stock is currently mid-range between its 52-week high and low $0.02 and $0.20. With a market capitalization of about $95.35 million, Zomedica Corp. is classified as a micro-cap and shows market-like volatility (beta ~1.16). Key stats such as the average daily volume over the past year has been around 8.54 million shares, volume is running light vs its 52-week average. Headquartered in Ann Arbor, MI, Zomedica Corp. operates in the Healthcare sector and the Drug Manufacturers - Specialty & Generic industry. Led by CEO Larry C. Heaton II, the company employs approximately 144 people and listed since November 21, 2017. Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals.

Technical Performance

ZOM has shown weak momentum, losing -71.13% over the past week and -76.35% over the past quarter, though year-to-date performance is down -74.83%. Short-term trend indicators are bullishly aligned (SMA20 -15.85%, SMA50 -20.38%, SMA200 -27.94%). The stock’s 14-day RSI is 22.05 (weak momentum), while the ATR of 0.0 points to tighter daily ranges. The stock remains hovering near 52-week lows, trading -50.15% below its high and over 5.76% above its low.

Valuation Metrics

Zomedica Corp. trades at a P/E ratio of -1.16, slightly below the S&P 500 average, with a price-to-sales ratio of 2.98 and a price-to-book ratio of 0.83 suggesting the stock is closer to book value. The P/FCF stands at -5.4, also below market averages.

Dividend & Fair Value

Zomedica Corp. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.14. This means the shares are trading below this model’s fair value.

Earnings & Analyst Outlook

Zomedica Corp. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended March 13, 2025, missed forecasts by 0.0%. The prior quarter beat by 40.06%. Over the last six quarters, Apple has recorded several small beats. These include 50.0% in February 26, 2020.

Shareholding & Insider Activity

Zomedica Corp. has 979.95 million shares outstanding. The public float is 961.65 million shares, elevated short interest at 4.63% of float. This equals 44.59 million shares. The short ratio is 6.22 days. Institutional investors hold 9.55% of the float. Insiders own 1.87%. Solensky Gerald JR holds 37.95 million shares, Klass Russell Kevin has 3.20 million shares and POWERS JOHNNY D has 2.52 million shares.

Financial & Profitability Overview

Over the trailing twelve months, Zomedica generated $32.03M in revenue, or $0.03 per share. Gross margin was 67.68%, operating margin -263.36%, and net profit margin -255.57%. Returns are negative, with ROA at -64.44% and ROE at -70.94%.
On valuation metrics, Zomedica trades at a P/E of -1.16, P/S of 2.98 and P/B of 0.83. The current ratio is 6.78 and quick ratio is 6.19. Operationally, the company’s inventory turnover is 1.87 and cash conversion cycle is 174.32 days. Debt-to-equity is 0.01, supported by a cash flow-to-debt ratio of -24.62.

Quarterly Financial Highlights

For the quarter ended Dec 31, 2025, Zomedica posted revenue of $32.03M, down slightly from $27.29M in the prior quarter. Gross profit was $21.68M (margin 67.68%). Operating income was - $84.35M (margin -263.4%). Net income was- $81.86M (EPS - $0.08).
The company ended the quarter with $53.26M in cash and short-term investments, a total debt of $717.00K, and net debt of - $8.30M. Total assets were $127.04M, with equity of $115.40M. Financials further reflected weakness, with operating cash flow of - $17.65M, free cash flow of - $17.65M, and capital expenditures of $0.00.

Price Forecast & Outlook

Our AI price prediction model suggests that Zomedica Corp. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -50.62%, with price expected at $0.03 by April 10, 2025, within a range of $0.01 to $0.05 3-Month Outlook: Projected rise of 295.06%, reaching $0.24 by June 04, 2025, with a range of $0.23 to $0.26. 1-Year Outlook: Projected gain of 2764.2%, with price at $1.74 by March 06, 2026, within a range of $0.00 to $1.05.

Key Takeaways

Zomedica Corp. (AMEX:ZOM) shares are down -74.83% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Zomedica Corp. trading at a premium to the broader market with a P/E of -1.16. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $6.00, suggesting 9776.54% upside. Our AI forecast model points to short-term weakness (-50.62% over two weeks), a medium-term rise (295.06% over three months), and a longer-term gain (2764.2% over one year), with expected trading ranges indicating moderate volatility.

Frequently Asked Questions

What is the current Zomedica Corp. (ZOM) stock price?

Zomedica Corp. (AMEX: ZOM) stock price is $0.10 in the last trading session. During the trading session, ZOM stock reached the peak price of $0.10 while $0.09 was the lowest point it dropped to. The percentage change in ZOM stock occurred in the recent session was -0.21% while the dollar amount for the price change in ZOM stock was - $0.00.

ZOM's industry and sector of operation?

The AMEX listed ZOM is part of Drug Manufacturers - Specialty & Generic industry that operates in the broader Healthcare sector. Zomedica Corp. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of ZOM?

Mr. Evan St. Peter
Vice President of Technology Innovation
Mr. Anthony K. Blair
Chief Operating Officer
Ms. Karen DeHaan-Fullerton J.D.
Gen. Counsel, Chief Counsel & Corporation Sec.
Dr. Stephanie Laine Morley D.V.M., DVM
Consultant
Dr. William Carpenter MacArthur
Consultant
Ms. Kristin Domanski
Vice President of HR
Mr. Larry C. Heaton II
Pres, Chief Executive Officer & Director
Ms. Nicole Westfall
Vice President of Marketing
Mr. Adrian Lock
Vice President, GM & Head of Sales
Ms. Ann Marie Cotter CPA
Chief Financial Officer
Mr. Robert W. DiMarzo
Consultant
Mr. Peter L. Donato BSBA, M.B.A.
Chief Financial Officer
Mr. Greg Blair
Vice President of Bus. Devel. & Strategic Planning
Ms. Karen L. DeHaan-Fullerton J.D.
Chief Counsel & Corporation Sec.

How ZOM did perform over past 52-week?

ZOM's closing price is 544.37% higher than its 52-week low of $0.02 where as its distance from 52-week high of $0.20 is -50.15%.

How many employees does ZOM have?

Number of ZOM employees currently stands at 144.

Link for ZOM official website?

Official Website of ZOM is: https://www.zomedica.com

How do I contact ZOM?

ZOM could be contacted at phone 734 369 2555 and can also be accessed through its website. ZOM operates from 100 Phoenix Drive, Ann Arbor, MI 48108, United States.

How many shares of ZOM are traded daily?

ZOM stock volume for the day was 790.94K shares. The average number of ZOM shares traded daily for last 3 months was 8.54M.

What is the market cap of ZOM currently?

The market value of ZOM currently stands at $95.35M with its latest stock price at $0.10 and 979.95M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	144
Beta	1.16
Sales or Revenue	$32.03M
5Y Sales Change%	0%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic

ZOM Company Profile and Key Details

Zomedica

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Technical Performance

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways